Ocular Therapeutix Taking Aim at Allergy Market

Amar Sawhney, PhD, Chairman, Chairman, President & CEO of Ocular Therapeutics, touts the performance of Dextenza, the company’s anti-allergy medication. Instead of taking one drop a day, allergy sufferers just need one treatmet of Dextenza to survive a whole season.

Speaking With:


Amar Sawhney, PhD

Amarpreet Sawhney, Ph.D., co-founded Ocular Therapeautix in 2006, has since served as President and CEO and was elected Chairman of the Board in 2014. Dr. Sawhney served as CEO of Augmenix, from 2008 until 2014 and is a general partner of Incept, LLC, an intellectual property holding company.

View Full Profile